Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2016
At a glance
- Drugs Sodium oligomannurarate (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Shanghai Green Valley Pharmaceutical
- 08 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
- 08 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
- 21 Nov 2014 New trial record